Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | G6PD | P11413 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.58 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.57 |
| ▸ | DPP4 | P27487 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Helicide SCHEMBL23457333 | 1.00 | TYR (0.69) | TYRKDM4EPOLBGAAMAPT | |
| Helicide SCHEMBL5030879 | 1.00 | TYR (0.69) | TYRKDM4EPOLBGAAMAPT | |
| Helicide SCHEMBL17822698 | 1.00 | TYR (0.69) | TYRKDM4EPOLBGAAMAPT | |
| Helicide SCHEMBL467669 | 1.00 | TYR (0.69) | TYRKDM4EPOLBGAAMAPT | |
| Helicide SCHEMBL9426962 | 1.00 | TYR (0.69) | TYRKDM4EPOLBGAAMAPT | |
| SCHEMBL6842994 | 0.99 | TYR (0.67) | TYRKDM4EPOLBGAAMAPT | |
| SCHEMBL6842995 | 0.99 | TYR (0.67) | TYRKDM4EPOLBGAAMAPT | |
| SCHEMBL9189048 | 0.88 | KDM4E (0.59) | TYRKDM4EPOLBGAAMAPT | |
| SCHEMBL16785945 | 0.88 | TYR (0.87) | TYRKDM4EPOLBGAAMAPT | |
| SCHEMBL17366540 | 0.88 | TYR (0.87) | TYRKDM4EPOLBGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152614-A1 | Compositions And Methods For Inducing Apoptosis In Anaerobic Cells And Related Clinical Methods For Treating Cancer And Pathogenic Infections | ROBERTS SUZANNAH JANE (US) | 2025-05-15 | — | — | US | claimed |
| US-20240316087-A1 | Compositions And Methods For Inducing Apoptosis In Anaerobic Cells And Related Clinical Methods For Treating Cancer And Pathogenic Infections | ROBERTS SUZANNAH JANE (US) | 2024-09-26 | — | — | US | claimed |
| US-20240050458-A1 | Compositions And Methods For Inducing Apopotosis In Anaerobic Cells And Related Clinical Methods For Treating Cancer And Pathogenic Infections | ROBERTS SUZANNAH JANE (US) | 2024-02-15 | — | — | US | claimed |
| US-20200360408-A1 | Compositions And Methods For Inducing Apoptosis In Anaerobic Cells And Related Clinical Methods For Treating Cancer And Pathogenic Infections | COGNATE 3 LLC | 2020-11-19 | — | — | US | claimed |
| US-20200253998-A1 | Compositions And Methods For Immunotherapy | BROWN JOE ERNEST (US) | 2020-08-13 | — | — | US | claimed |
| US-20160113955-A1 | Compositions And Methods For Immunotherapy | BROWN JOE ERNEST (US) | 2016-04-28 | — | — | US | claimed |
| US-20160008388-A1 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | BROWN JOE ERNEST (US) | 2016-01-14 | — | — | US | claimed |
| US-20120251490-A1 | Compositions And Methods For Immunotherapy | BROWN JOE ERNEST (US) | 2012-10-04 | — | — | US | claimed |
| US-20110311478-A1 | Combinatorial Methods For Treating Cellular Proliferative Disorders And Immune Deficiencies Using Salicinium | BROWN JOE ERNEST (US) | 2011-12-22 | — | — | US | claimed |
| US-20110311477-A1 | Infusion Treatment Methods And Compositions Using Salicinium For Treating Cellular Proliferative Disorders And Immune Deficiencies | BROWN JOE ERNEST (US) | 2011-12-22 | — | — | US | claimed |
| US-20110311476-A1 | Methods For Treating An Immune Deficiency Or Enhancing Immune Function Using Salicinium, Non-Limited In Terms Of Treatment Indication, But Encompassing Methods For Treating Cancer And Microbial, Bacterial, Viral, Fungal; Non-Limited In Terms of Delivery Mode, Formulation | BROWN JOE ERNEST (US) | 2011-12-22 | — | — | US | claimed |
| EP-2271350-A1 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | Cognate3, LLC. (US) | 2011-01-12 | — | — | EP | claimed |
| WO-2009145841-A1 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | COGNATE 3, LLC (US) | 2009-12-03 | — | — | WO | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2025-07-03 | — | — | US | disclosed |
| US-20250177374-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2025-06-05 | — | — | US | disclosed |
| EP-2271350-A1 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | Cognate3, LLC. (US) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009145841-A1 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | COGNATE 3, LLC (US) | 2009-12-03 | — | — | WO | disclosed |
| US-20090281047-A1 | Compositions And Methods For Immunotherapy | COGNATE3 LLC | 2009-11-12 | — | — | US | disclosed |
| EP-0455432-B1 | Alpha-glycosyl naringin, and its preparation and uses | HAYASHIBARA BIOCHEM LAB (JP) | 1996-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160008388-A1 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | ICOS, IL2, NFATC1 | TYR 553/4885KDM4E 2739/4885POLB 638/4885 |
| US-20090281047-A1 | Compositions And Methods For Immunotherapy | ICOS, IL2, NFATC1 | TYR 553/4885KDM4E 2739/4885POLB 638/4885 |
| US-20240050458-A1 | Compositions And Methods For Inducing Apopotosis In Anaerobic Cells And Related Clinical Methods For Treating Cancer And Pathogenic Infections | ENGASE, AGL, GAA | TYR 877/4885KDM4E 2840/4885POLB 992/4885 |
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | TYR 3490/4885KDM4E 1013/4885POLB 3852/4885 |
| US-20110311478-A1 | Combinatorial Methods For Treating Cellular Proliferative Disorders And Immune Deficiencies Using Salicinium | NFATC1, MKI67, MYD88 | TYR 1389/4885KDM4E 3095/4885POLB 539/4885 |
| US-20110311477-A1 | Infusion Treatment Methods And Compositions Using Salicinium For Treating Cellular Proliferative Disorders And Immune Deficiencies | IDO1, MKI67, ADSL | TYR 1401/4885KDM4E 3215/4885POLB 532/4885 |
| US-20110311476-A1 | Methods For Treating An Immune Deficiency Or Enhancing Immune Function Using Salicinium, Non-Limited In Terms Of Treatment Indication, But Encompassing Methods For Treating Cancer And Microbial, Bacterial, Viral, Fungal; Non-Limited In Terms of Delivery Mode, Formulation | IDO1, TLR5, IDO2 | TYR 937/4885KDM4E 1411/4885POLB 1318/4885 |
| US-20240316087-A1 | Compositions And Methods For Inducing Apoptosis In Anaerobic Cells And Related Clinical Methods For Treating Cancer And Pathogenic Infections | ENGASE, AGL, GAA | TYR 2234/4885KDM4E 1749/4885POLB 966/4885 |
| US-20120251490-A1 | Compositions And Methods For Immunotherapy | ICOS, IL2, NFATC1 | TYR 553/4885KDM4E 2739/4885POLB 638/4885 |
| US-20200360408-A1 | Compositions And Methods For Inducing Apoptosis In Anaerobic Cells And Related Clinical Methods For Treating Cancer And Pathogenic Infections | ENGASE, AGL, GAA | TYR 2234/4885KDM4E 1749/4885POLB 966/4885 |
| US-20200253998-A1 | Compositions And Methods For Immunotherapy | ICOS, NFATC1, IL2 | TYR 630/4885KDM4E 3257/4885POLB 774/4885 |
| US-20160113955-A1 | Compositions And Methods For Immunotherapy | ICOS, IL2, NFATC1 | TYR 553/4885KDM4E 2739/4885POLB 638/4885 |
| US-20250152614-A1 | Compositions And Methods For Inducing Apoptosis In Anaerobic Cells And Related Clinical Methods For Treating Cancer And Pathogenic Infections | ENGASE, AGL, GAA | TYR 2234/4885KDM4E 1749/4885POLB 966/4885 |
| US-20250177374-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | TYR 4528/4885KDM4E 1299/4885POLB 4027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.